PP
PLRX icon

PDT Partners’s Pliant Therapeutics PLRX Stock Holding History

PDT Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-63,352
Closed -$681K – 800
2024
Q2 		$681K Buy
+63,352
New +$817K 0.06% 415
2022
Q3 		– Sell
-24,378
Closed -$195K – 1029
2022
Q2 		$195K Buy
+24,378
New +$156K 0.02% 832

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

PDT Partners's PLRX Position: Q3 2024 in Review

PDT Partners sold out of Pliant Therapeutics (PLRX) in Q3 2024, closing a stake of 63,352 shares — an estimated $681K sold.

PDT Partners first reported a position in PLRX in Q2 2022 and held it in 2 quarters. The position peaked at $681K in Q2 2024. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • PDT Partners reported no remaining Pliant Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PDT Partners sold 63,352 Pliant Therapeutics shares in Q3 2024, an estimated $681K.
  • PDT Partners first reported a position in Pliant Therapeutics in Q2 2022 and held it in 2 quarters.
  • PDT Partners's Pliant Therapeutics position peaked at $681K in Q2 2024.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on PDT Partners's 13F filing for Q3 2024, filed 14 Nov 2024.